Long-Term Evaluation of Post-transplant Lymphoproliferative Disorders in Paediatric Heart Transplantation in Sao Paulo, Brazil

Carregando...
Imagem de Miniatura
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2019
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER
Citação
PEDIATRIC CARDIOLOGY, v.40, n.8, p.1655-1662, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
We sought to better define the demographics and characteristics of post-transplant lymphoproliferative disorders (PTLD) in a cohort of paediatric OHT patients from a developing country. Data were collected from the Heart Institute, Sao Paulo, for all paediatric OHT recipients from October 1992 to October 2018. Group differences between the PTLD and non-PTLD cohorts were assessed by Fisher exact and Mann-Whitney U tests. Kaplan-Meier curves analysed the survival in each group. Data were reviewed for 202 paediatric OHT recipients. Overall 1-, 5- and 10-year survival for the entire cohort was 76.5%, 68.3% and 62.9%; 24 patients (11.9%) developed PTLD at a median 3.1 years (IQR 0.8-9.0) after OHT. Cases were evenly spread over the follow-up period, with PTLD diagnosed in 9.8% (n = 137) of patients who were alive at 3 years, 15.3% (n = 78) of patients who were alive at 5 years and 29.3% (n = 41) of patients who were alive at 10 years. The commonest form of PTLD was diffuse large B cell lymphoma (n = 9), and most patients received rituximab with immunosuppression and chemotherapy as treatment (n = 15). We identified no increased risk in mortality amongst the PTLD vs. non-PTLD cohorts in multivariate analysis (P = 0.365). PTLD after paediatric OHT had acceptable outcomes. However, risk factors for PTLD were not identified and warrant further investigation.
Palavras-chave
Heart clinical, Complications-heart clinical, Paediatric transplantation
Referências
  1. Allen UD, 2013, AM J TRANSPLANT, V13, P107, DOI 10.1111/ajt.12104
  2. Arvin A, 2007, HUMAN HERPESVIRUSES: BIOLOGY, THERAPY, AND IMMUNOPROPHYLAXIS, P700
  3. Azeka E, 2014, TRANSPL P, V46, P1842, DOI 10.1016/j.transproceed.2014.05.050
  4. BERNSTEIN D, 1993, CIRCULATION, V88, P230
  5. Bocchi EA, 2001, J HEART LUNG TRANSPL, V20, P637, DOI 10.1016/S1053-2498(00)00235-7
  6. Boucek MM, 2003, J HEART LUNG TRANSPL, V22, P636, DOI 10.1016/S1053-2498(03)00184-0
  7. Chinnock R, 2012, AM J TRANSPLANT, V12, P3061, DOI 10.1111/j.1600-6143.2012.04197.x
  8. Dipchand AI, 2018, ANN CARDIOTHORAC SUR, V7, P31, DOI 10.21037/acs.2018.01.07
  9. Green M, 2013, AM J TRANSPLANT, V13, P41, DOI 10.1111/ajt.12004
  10. Gross TG, 2012, AM J TRANSPLANT, V12, P3069, DOI 10.1111/j.1600-6143.2012.04206.x
  11. Hayes D, 2015, PEDIATR CARDIOL, V36, P1748, DOI 10.1007/s00246-015-1229-y
  12. Lee HY, 2017, CIRC J, V81, P617, DOI 10.1253/circj.CJ-17-0162
  13. Lund LH, 2017, J HEART LUNG TRANSPL, V36, P1037, DOI 10.1016/j.healun.2017.07.019
  14. Manlhiot C, 2010, J HEART LUNG TRANSPL, V29, P648, DOI 10.1016/j.healun.2010.01.013
  15. Mendoza F, 2006, PEDIATR TRANSPLANT, V10, P60, DOI 10.1111/j.1399-3046.2005.00401.x
  16. Oertel SHK, 2005, AM J TRANSPLANT, V5, P2901, DOI 10.1111/j.1600-6143.2005.01098.x
  17. Petrara MR, 2015, CANCER LETT, V369, P37, DOI 10.1016/j.canlet.2015.08.007
  18. Rossano JW, 2016, J HEART LUNG TRANSPL, V35, P1185, DOI 10.1016/j.healun.2016.08.018
  19. Rudge C, 2012, BRIT J ANAESTH, V108, pI48, DOI 10.1093/bja/aer399
  20. Schubert S, 2009, PEDIATR TRANSPLANT, V13, P54, DOI 10.1111/j.1399-3046.2008.00969.x
  21. Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569
  22. Webber SA, 2006, LANCET, V367, P233, DOI 10.1016/S0140-6736(06)67933-6